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Since the discovery of radiolabelled octreotide and the suc-
cessful introduction into clinical practice of Octreoscan®, it
has been expected that radiolabelled peptides would become a
newclassofradiopharmaceuticalsforcancerimaging.Indeed,
as e r i e so fr e c e p t o rb i n d i n gp e p t i d ea n a l o g u e s ,s u c ha sc h o l e -
cystokinin (CCK)/gastrin, bombesin, vasoactive intestinal
protein, neurotensin and others, has been tested for imaging
receptor-expressing tumours in animal models. However,
clearly their introduction into clinical practice is still awaited.
InthisissueoftheEuropeanJournalofNuclearMedicineand
Molecular Imaging, Kiesewetter et al. describe the feasibility
of imaging insulinoma with
18F-labelled exendin [5], which
c o u l db ec o n s i d e r e da sam a j o rs t e pf o r w a r di nt h e
development of another peptide-based tracer for tumour
imaging. Exendin was tested more than a decade ago for
the first time to image tumours expressing the glucagon-
like peptide (GLP-1) receptor on their cell surface [4].
Exendin is a 39-amino acid peptide found in the saliva of
the Gila monster, which binds to the incretin hormone
receptor, GLP-1R. This receptor is expressed generally in
low amounts in specific tissue compartments of several
organs, such as pancreas, intestine, lung, kidney, breast
and brain [7]. The endogenous ligands of the GLP-1R,
GLP-1 and gastric inhibitory peptide are rapidly degrad-
ed by the enzyme dipeptidyl peptidase IV [8]. Therefore,
the GLP-1 analogue exendin was proposed for targeting
GLP-1R-expressing tumours. Among others, the GLP-1R
is especially expressed in insulinomas, particularly the
more common benign tumours [7]. Although insulinomas
are a rare tumour type with an incidence estimated at one
to four new cases per million people per year, the clin-
ical relevance of insulinoma imaging lies in the exact
preoperative localization of the tumours. This could help
the surgeon in planning accurate resection, thus poten-
tially reducing surgical complications [9].
In Rip1Tag2 mice that spontaneously develop GLP-
1R-expressing insulinomas, Wicki et al. [11]h a v es h o w n
that
111In-labelled exendin-4 extremely efficiently targeted
the insulinoma lesions: uptake in the lesions exceeded
200%ID/g. Despite the high intrinsic kidney uptake of the
tracer (190%ID/g), they showed that high doses of
111In-
exendin-4 (28 MBq/mouse) inhibited the growth of the
lesions. More importantly, the same group showed that
111In-exendin-4 accurately visualized the localization of
insulinomas in patients [12]. Exendin-4 was also labelled
with
99mTc by C-terminally conjugating HYNIC [13],
which could make the peptide even more attractive for
imaging insulinoma with single photon emission computed
tomography (SPECT) in patients.
The new challenge is to develop an exendin-based posi-
tron emission tomography (PET) tracer for insulinoma im-
aging, which would allow more accurate determination of
the localization and extent of the insulinoma. DOTA-
conjugated exendin-3 could be labelled with high efficiency
with
68Ga and the in vivo characteristics of this tracer were
determined by microPET imaging of nude mice with s.c.
GLP-1R-expressing INS xenografts [2]. For PETimaging of
insulinomas an
18F-labelled tracer would have additional
advantages over a tracer labelled with
68Ga: (1) the option
to acquire images beyond 2 h post-injection due the longer
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18F and (2) higher resolution of the images due to
the lower positron energy. However, the development of an
18F-labelled version of exendin is a challenge, particularly
because a tracer with a high specific activity is required. In
mice with s.c. INS tumours it has been shown that optimal
tracer uptake in the GLP-1R-expressing tumours could only
be obtained at a peptide dose of 22 pmol (00.1 μg) or lower
per mouse, indicating that for microPET a specific activity
of 200 GBq/μmol would be required for imaging at the
optimal peptide dose. In the study presented in the present
issue of the European Journal of Nuclear Medicine and
Molecular Imaging, Kiesewetter et al. [5] succeeded in
producing a tracer that met this requirement. They elegantly
exploited the very efficient reaction between a maleimide
and a thiol group, by reacting the
18F-labelled FBEM with
[Cys40]-exendin-4 with a 35% yield. Using this synthetic
route
18F-labelled exendin-4 could be produced with a spe-
cific activity of 45 GBq/μmol. The tracer was stable in
blood and had a high affinity for the GLP-1R (IC5001.2±
0.1 nmol). Upon i.v. injection in nude mice, the tracer accu-
mulated rapidly in the GLP-1R-expressing s.c. insulinoma
xenografts (7.2%ID/g), whereas uptake in GLP-1R-negative
tumours was tenfold lower. The tracer could be synthesized
within1 h,opening the way for PETimaging ofinsulinomain
patients.
Potentially this tracer could be applied much more widely,
as the GLP-1R is also expressed on the insulin-
producing beta cells in the pancreas. Recently, it was
shown that radiolabelled exendin could also be used to
monitor the survival of transplanted beta cells [1, 9].
Beta cell transplantation currently is an experimental
therapy for patients with type I diabetes. However,
survival of the transplant is limited because of immu-
nological rejections as well as metabolic stress factors
following transplantation.
18F-Exendin could potentially
be used to longitudinally monitor the viability of trans-
planted beta cells. In addition, the tracer could be used
to determine the beta cell mass in the pancreas. In type
1 diabetes, autoimmune destruction of pancreatic beta
cells leads to an absolute deficiency of insulin secretion
withhyperglycaemiaasaconsequence.Ithasbeenshownthat
there is a reserve capacity of beta cells and that type 1
diabetes only becomes clinically apparent when the beta
cell mass drops under a critical threshold (< 30%) [6,
10]. The beta cell mass also changes during the devel-
opmentand courseoftype2diabetes[3].If
18F-exendin could
be used to quantitatively determine the pancreatic beta cell
mass in vivo, this would allow studies that give further
insight into the pathogenesis and development of type 1
and 2 diabetes. If clinical studies will show that the
beta cell mass could be accurately quantitatively deter-
mined with PET with
18F-exendin in patients developing
diabetes, after radiolabelled octreotide,
18F-labelled exendin
might bethe secondpeptide-based tracerthatcould beapplied
widely in the clinical setting.
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